Education
About Us
Working with TipRanks
Follow Us
ALK-abello A/S Class B (AKBLF)
OTHER OTC:AKBLF
AKBLF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.45 - $33.50
Previous CloseN/A
Volume1.00
Average Volume (3M)0.00
Market Cap
$7.04B
Enterprise Value$41.49B
Total Cash (Recent Filing)$316.00M
Total Debt (Recent Filing)$990.00M
Price to Earnings (P/E)48.6
Beta0.59
Next Earnings
Nov 13, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 16, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding202,567,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap5.89
Enterprise Value/Revenue7.27
Enterprise Value/Gross Profit11.28
Enterprise Value/Ebitda26.74
Forecast
1Y Price Target
$28.17Price Target Upside-11.75% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering0
ALK-abello News
AKBLF FAQ
What was ALK-abello A/S Class B’s price range in the past 12 months?
ALK-abello A/S Class B lowest stock price was $18.45 and its highest was $33.50 in the past 12 months.
What is ALK-abello A/S Class B’s market cap?
ALK-abello A/S Class B’s market cap is $7.04B.
When is ALK-abello A/S Class B’s upcoming earnings report date?
ALK-abello A/S Class B’s upcoming earnings report date is Nov 13, 2025 which is in 63 days.
How were ALK-abello A/S Class B’s earnings last quarter?
ALK-abello A/S Class B released its earnings results on Aug 21, 2025. The company reported $0.186 earnings per share for the quarter, missing the consensus estimate of $0.204 by -$0.018.
Is ALK-abello A/S Class B overvalued?
According to Wall Street analysts ALK-abello A/S Class B’s price is currently Overvalued.
Does ALK-abello A/S Class B pay dividends?
ALK-abello A/S Class B pays a Annually dividend of $0.25 which represents an annual dividend yield of N/A. See more information on ALK-abello A/S Class B dividends here
What is ALK-abello A/S Class B’s EPS estimate?
ALK-abello A/S Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ALK-abello A/S Class B have?
ALK-abello A/S Class B has 202,567,200 shares outstanding.
What happened to ALK-abello A/S Class B’s price movement after its last earnings report?
ALK-abello A/S Class B reported an EPS of $0.186 in its last earnings report, missing expectations of $0.204. Following the earnings report the stock price went up 3.63%.
Which hedge fund is a major shareholder of ALK-abello A/S Class B?
Currently, no hedge funds are holding shares in AKBLF
Company Description
ALK-abello A/S Class B
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
AKBLF Company Deck
AKBLF Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue and earnings growth, with successful product launches and an upgraded revenue outlook. However, challenges in China, SCIT sales decline, and supply constraints in Japan were noted as areas of concern.View all AKBLF earnings summariesTechnical Analysis
Dynavax
―
Inovio Pharmaceuticals
―
Aclaris Therapeutics
―
Emergent Biosolutions
―
Novartis
―
Bristol-Myers Squibb
―
Ownership Overview
0.03% Insiders
3.65% Mutual Funds
― Other Institutional Investors
92.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---